High-dose benznidazole in a 62-year-old Bolivian kidney transplant recipient with Chagas central nervous system involvement

•Chagas disease, caused by Trypanosoma cruzi, is a global problem with an increasing impact on public health.•Trypanosoma cruzi reactivation may occur in immunosuppressed patients, so it should be taken into account in the screening and differential diagnosis of patients from endemic areas.•Only ben...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of infectious diseases Vol. 78; pp. 103 - 106
Main Authors:	Montero, M., Mir, M., Sulleiro, E., Avalos Esquivel, J.L., García López, E., Molina-Morant, D., López Montesinos, I., Sorlí, L., Veliz Espinosa, G., Mounteis Oliva, E., Crespo, M., Monge, I., Horcajada, J.P., Grau, S., Pascual, J.
Format:	Journal Article
Language:	English
Published:	Canada Elsevier Ltd 01-01-2019 Elsevier
Subjects:	Benznidazole dose Benznidazole PK/PD Brain - metabolism Chagas disease Chagas Disease - immunology Chagas, Malaltia de Chagoma Humans Immunocompromised Host Immunosuppressive Agents - administration & dosage Kidney transplant recipient Kidney Transplantation Male Middle Aged Nitroimidazoles - administration & dosage Nitroimidazoles - pharmacokinetics Ronyons Trasplantació Chagas disease Chagoma Benznidazole dose Kidney transplant recipient Benznidazole PK/PD
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•Chagas disease, caused by Trypanosoma cruzi, is a global problem with an increasing impact on public health.•Trypanosoma cruzi reactivation may occur in immunosuppressed patients, so it should be taken into account in the screening and differential diagnosis of patients from endemic areas.•Only benznidazole and nifurtimox have been approved for use in the treatment of patients with Chagas disease, a current worldwide health problem.•There is dearth of available information on benznidazole dosage and the levels achieved in cerebrospinal fluid. There is little published data on benznidazole dosing, or levels in cerebrospinal fluid. In this report, we describe the clinical course of an immunosuppressed patient with Chagas central nervous system involvement. He was treated successfully with larger benznidazole doses than are recommended, in order to reach therapeutically effective concentrations in the brain.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1201-9712 1878-3511
DOI:	10.1016/j.ijid.2018.10.014